The Histone Acetylase Activator Pentadecylidenemalonate 1b Rescues Proliferation and Differentiation in Human Cardiac Mesenchymal Cells of Type 2 Diabetic Patients
- Matteo Vecellio1,8,#§,
- Francesco Spallotta1,8,#,
- Simona Nanni2,#,
- Claudia Colussi2,
- Chiara Cencioni8,
- Anja Derlet11,
- Beatrice Bassetti1,
- Manuela Tilenni1,
- Maria Cristina Carena1,8,§,
- Antonella Farsetti4,
- Gianluca Sbardella5,
- Sabrina Castellano5,
- Antonello Mai6,
- Fabio Martelli10,
- Giulio Pompilio1,
- Maurizio C. Capogrossi7,
- Alessandra Rossini3,
- Stefanie Dimmeler11,
- Andreas M. Zeiher9 and
- Carlo Gaetano8,*
- 1Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino, Milano, Italy
- 2Institute of Medical Pathology, Catholic University of Rome, Policlinico A. Gemelli, Roma, Italy.
- 3Department of Clinical Sciences and Community Health, University of Milano, Milano, Italy.
- 4Consiglio Nazionale delle Ricerche, IBCN, Roma, Italy.
- 5Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Fisciano (SA), Italy.
- 6Department of Drug Chemistry and Technology, University of Rome, Rome, Italy.
- 7Laboratorio di Patologia Vascolare, Istituto Dermopatico dell’Immacolata, Rome, Italy.
- 8Division of Cardiovascular Epigenetics, Department of Cardiology - Goethe University, Frankfurt am Main, Germany.
- 9Internal Medicine Clinic III, Department of Cardiology - Goethe University, Frankfurt am Main, Germany.
- 10IRCCS Policlinico San Donato, Laboratorio di Cardiologia Molecolare, San Donato Milanese, Milano, Italy.
- 11Institute of Cardiovascular regeneration, Goethe University, Frankfurt am Main, Germany.
- *Corresponding Author: Carlo Gaetano, Email: or
This study investigates the diabetes-associated alterations present in cardiac mesenchymal cells (CMSC) obtained from normoglycaemic (ND-CMSC) and Type-2 diabetes patients (D-CMSC), identifying the histone acetylase (HAT) activator pentadecylidenemalonate 1b (SPV106) as a potential pharmacological intervention to restore cellular function. D-CMSC were characterized by a reduced proliferation rate, diminished phosphorylation at histone H3 Serine 10 (H3S10P), decreased differentiation potential and premature cellular senescence. A global histone code profiling of D-CMSC revealed that acetylation on histone H3 Lysine 9 and Lysine 14 (H3K9Ac; H3K14Ac) was decreased while the trimethylation of histone H3 Lysine 9 and Lysine 27 (H3K9Me3; H3K27Me3) significantly increased. These observations were paralleled by a down-regulation of the GCN5-Related N-acetyltransferases (GNAT) p300/CBP associated factor (PCAF) and its isoform 5-alpha General Control of Amino Acid Synthesis (GCN5a), determining a relative decrease in total HAT activity. DNA CpG island hyper methylation was detected at promoters of genes involved in cell growth control and genomic stability. Remarkably, treatment with the GNAT pro-activator SPV106, restored normal levels of H3K9Ac and H3K14Ac, reduced DNA CpG hyper methylation and recovered D-CMSC proliferation and differentiation. These results suggest that epigenetic interventions may reverse alterations in human cardiac mesenchymal cells obtained from diabetic patients.
§ current address: University of Oxford, Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK.
# These authors equally contributed to this work.
- Received May 7, 2013.
- Accepted January 14, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.